Exploration of treatment options for the management of stage I testicular seminoma

Federico Bernal, Jay Raman

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Seminoma is the epitome of a highly treatable neoplastic malignancy. Approximately 80% of patients presenting with seminomatous germ cell tumors are diagnosed with stage I disease. Men with clinical stage I seminomas have an excellent chance of achieving a cure irrespective of the treatment option selected. With such high disease-specific survival rates, attention has turned to reducing treatment-related morbidity. Adjuvant radiotherapy to the para-aortic retroperitoneal lymph nodes in conjunction with orchidectomy has been the standard treatment since the mid-1990s. There is some evidence, however, suggesting potential deleterious long-term sequelae from radiation treatment. Adjuvant chemotherapy has gained support as an acceptable adjuvant treatment strategy for stage I seminoma. While long-term studies are limited, short-term data regarding the therapeutic efficacy of single-agent carboplatin are promising. Finally, surveillance following orchidectomy is an attractive option for motivated patients interested in avoiding immediate adjuvant therapy. It may be the optimal choice for compliant men who are able to handle the mental burden of not receiving active treatment.

Original languageEnglish (US)
Pages (from-to)1081-1090
Number of pages10
JournalExpert Review of Anticancer Therapy
Issue number7
StatePublished - 2008

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Exploration of treatment options for the management of stage I testicular seminoma'. Together they form a unique fingerprint.

Cite this